Welcome
Just a quick word to tell you how thrilled I am to welcome you to BioSquare 2010…
Indeed, despite the ’08-09’ economic crisis, the BioSquare team have chosen to upgrade and refine BioSquare. In no uncertain terms, we pledge this event will mark a paradigm shift in the way PHARMACEUTICAL, BIOTECH PHARMAS, NANOTECH, MEDTECH and IN SILICO companies build partnerships.
I look forward to greeting you personally.
Bernadette Guagliata
CEO
BioSquare V2.0
Fact
Effective partnering opportunities lead to successful ventures.
Fact
Biotech, medtech, nanotech and in silico sectors are coming together as never before; we are witnessing the birth of bioconvergence.
Fact
The new BioSquare is the premiere bioconvergence partnering meeting for mature companies, high potential start-ups or willing investors working in the bioconvergence universe worldwide.
Fact
Expect an event that adds to your bottom line.
Did we mention it’s going to be the most enjoyable BioSquare ever?
BioSquare V2.0 Highlights
BioSquare has set high goals. It has also retained key fundamentals.
|
| Make valuable business connectionsThe one-to-one paradigm lives on but with major changes. You will meet people in far more comfort, with greater privacy and with superior presentation options. |
Who should attend?
BioSquare targets decision-makers that are ready to deal.
Historically, 46% of BioSquare attendees are President/CEO/Partner level, 21% are Senior VP/Director level and the remainder is academia, media and middle management. Over the last three BioSquare events the trend has been leaning towards higher-level attendees (President/CEO/Partner).
Sectorially, those that have regularly attended BioSquare are bio-technology companies, medical-technology companies, nano-technology companies, diagnostics, pharmaceutical, technology licensing offices, major research institutions, high potential start-ups and investment companies and individuals — without planning on it, we were a bioconvergence event all along.
Clearly, all life sciences players are welcome, but our focus is on companies that are sufficiently mature in their development to warrant an imminent investment or partnership.








